BOSTON--(BUSINESS WIRE)--Pi-Cardia Inc., a global leader in the development of leaflet modification solutions for treating heart valves, announced today the first commercial procedures with ShortCut ™ ...
REHOVOT, Israel--(BUSINESS WIRE)--Pi-Cardia Ltd., a global leader in the development of leaflet modification solutions for treating heart valves, announced today that the United States Food and Drug ...
Pi-Cardia, developer of leaflet modification solutions for treating heart valves, today announced it has received FDA Breakthrough Device Designation for ShortCut, a leaflet modification device used ...
The Pi-Cardia Ltd. Shortcut — the catheter-based, leaflet modification solution for treating heart valves — received U.S. FDA clearance. The device was granted breakthrough device designation from the ...
PARIS -- For people undergoing valve-in-valve transcatheter aortic valve replacement (TAVR), a dedicated bioprosthetic leaflet splitting device produced better-than-expected results preventing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results